Oxidoreductases, N-Demethylating

• 

  Subject Areas on Research

  • 3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency. 
  • Analysis of medaka cytochrome P450 3A homotropic and heterotropic cooperativity. 
  • Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. 
  • Biotransformation of sevoflurane. 
  • Characterization of the effects of tebufelone on hepatic cytochromes P450 in the beagle dog. 
  • Clinical enflurane metabolism by cytochrome P450 2E1. 
  • Clinical sevoflurane metabolism and disposition. II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation. 
  • DEET (N,N-diethyl-m-toluamide) alone and in combination with permethrin increased urinary excretion of 6beta-hydroxycortisol in rats, a marker of hepatic CYP3A induction. 
  • Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. 
  • Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. 
  • Effect of age and gender on the activity of human hepatic CYP3A. 
  • Effect of normal aging on the activity of human hepatic cytochrome P450IIE1. 
  • Effects of carbon tetrachloride on adrenocortical structure and function in guinea pigs. 
  • Enantiomeric metabolic interactions and stereoselective human methadone metabolism. 
  • Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B. 
  • HIF-miR-215-KDM1B promotes glioma-initiating cell adaptation to hypoxia. 
  • Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. 
  • Identification and characterization of a cDNA encoding cytochrome P450 3A from the fresh water teleost medaka (Oryzias latipes). 
  • Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance. 
  • Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. 
  • Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. 
  • Identification, characterization, and ontogeny of a second cytochrome P450 3A gene from the fresh water teleost medaka (Oryzias latipes). 
  • Induction of cytochrome P450 isozymes by simultaneous inhalation exposure of hens to n-hexane and methyl iso-butyl ketone (MiBK). 
  • Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. 
  • Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. 
  • Mechanism of autoinduction of methadone N-demethylation in human hepatocytes. 
  • Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. 
  • Metabolism of N-alkyl compounds during the biosynthesis of prostaglandins. N-Dealkylation during prostaglandin biosynthesis. 
  • Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. 
  • Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. 
  • Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites. 
  • Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6. 
  • MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. 
  • Molecular characterization of CYP2B6 substrates. 
  • N6-Methyladenosine in Flaviviridae Viral RNA Genomes Regulates Infection. 
  • Opposing LSD1 complexes function in developmental gene activation and repression programmes. 
  • Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. 
  • Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. 
  • Regulation of rat hepatic cytochrome P450IIE1 in primary monolayer hepatocyte culture. 
  • Relationship between cytochrome P450 2E1 and acetone catabolism in rats as studied with diallyl sulfide as an inhibitor. 
  • Role of CYP2B6 in stereoselective human methadone metabolism. 
  • Role of cytochrome P4502B6 in methadone metabolism and clearance. 
  • Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats. 
  • Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. 
  • Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. 
  • Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. 
  • Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. 
  • Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes. 
  • Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1. 
  • The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. 
  • Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. 
  • Use of pH and kinetic isotope effects to establish chemistry as rate-limiting in oxidation of a peptide substrate by LSD1. 
  • trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.